Biotech

Nanollose Limited (ASX:NC6) Quarterly Activities Report

🕔1/31/2022 9:41:56 AM

Nanollose Limited (ASX:NC6) (FRA:N0L) is pleased to provide shareholders and investors with an overview of activities for the period ending 31 December 2021.

Read Full Article▸

VGI Health Technology Limited (NSX:VTL) Contract with Resonance Health (ASX:RHT)

🕔1/25/2022 8:42:00 AM

Invictus Ops Pty Ltd, a wholly owned subsidiary of NSX-listed VGI Health Technology Limited (NSX:VTL), is pleased to announce that it has contracted Resonance Health Ltd (ASX:RHT) to provide liver-fat quantification services for its clinical study on a potential new treatment for Non-Alcoholic Steatohepatitis.

Read Full Article▸

VGI Health Technology Limited (NSX:VTL) Nutraceutical Products Listed on Amazon

🕔1/20/2022 9:05:00 AM

Invictus Nutraceuticals, Inc. (Florida, USA), a wholly owned subsidiary of VGI Health Technology Limited (NSX:VTL), is pleased to announce that both NE1-Elite(R) and NE1-Heart(R) are now available for sale on Amazon in the United States.

Read Full Article▸

VGI Health Technology Limited (NSX:VTL) Quarterly update

🕔1/19/2022 10:08:00 AM

The Directors of VGI Health Technology Limited (NSX:VTL) are pleased to provide the following update for the quarter ending 31 December 2021.

Read Full Article▸

IQX Limited (NSX:IQX) FDA Breakthrough Devices Designation

🕔12/13/2021 10:10:00 AM

iQX Limited (NSX:IQX) has filed an application with the U.S Food and Drug Administration (FDA) for Breakthrough Device Designation.

Read Full Article▸

VGI Health Technology Limited (NSX:VTL) Patent application lodged

🕔12/7/2021 9:14:00 AM

VGI Health Technology Limited (NSX:VTL), is pleased to announce that its wholly-owned subsidiary, Invictus Biotechnology Pty Ltd, has lodged a new PCT Patent Application titled: 'Transmucosal delivery of tocotrienols' (PCT patent application number: PCT/AU2021/051449).

Read Full Article▸

VGI Health Technology Limited (NSX:VTL) partners with ENDRA Life Sciences in NAFLD/NASH Phase II Clinical Study

🕔11/29/2021 8:15:00 AM

In September 2015, a Phase Ia clinical study on IVB001 had positive topline data where all primary endpoints were achieved, including: confirmation of the bioavailability of the compound, with good plasma levels, dose relationship and duration of plasma levels achieved.

Read Full Article▸